The first-in-class, oral, potent, and selective small-molecule competitive inhibitor of anaplastic lymphoma kinase (ALK), crizotinib, was found to have a durable overall response rate and a median progression-free survival of 8.1 months in patients with ALK-positive non–small-cell lung cancer (NSCLC), according to results of a global phase 2 study presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with Lung Cancer.
After participating in this educational activity, participants should be better able to:
Identify patients with non–small-cell lung cancer (NSCLC) who may benefit from targeted treatment with an anaplastic lymphoma kinase (ALK) inhibitor.
Evaluate the safety and efficacy of ALK inhibitor for the management of advanced NSCLC.